Clinical trialPhase 1Withdrawn
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
A Pilot Study of a Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma
- Outcome
- Stopped earlyStudy never started (Other)
- Phase
- Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Start
- 3 May 2023
- Expected end
- 3 May 2023
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Percentage of patients who receive at least one dose of personalized neoantigen vaccine; Number of participants experiencing study drug-related toxicities
- Sponsor
- Other
- Results posted
- No
- Last update
- 9 May 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).